- Home
- GROY vs KROS Comparison
GROY vs KROS Comparison
Compare GROY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- KROS
- Stock Information
- Founded
- GROY 2020
- KROS 2015
- Country
- GROY Canada
- KROS United States
- Employees
- GROY N/A
- KROS N/A
- Industry
- GROY
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- KROS Health Care
- Exchange
- GROY Nasdaq
- KROS Nasdaq
- Market Cap
- GROY 618.0M
- KROS 565.0M
- IPO Year
- GROY 2021
- KROS 2020
- Fundamental
- Price
- GROY $3.65
- KROS $15.62
- Analyst Decision
- GROY Strong Buy
- KROS Buy
- Analyst Count
- GROY 5
- KROS 14
- Target Price
- GROY $4.86
- KROS $20.56
- AVG Volume (30 Days)
- GROY 2.7M
- KROS 412.4K
- Earning Date
- GROY 11-03-2025
- KROS 11-05-2025
- Dividend Yield
- GROY N/A
- KROS N/A
- EPS Growth
- GROY N/A
- KROS N/A
- EPS
- GROY N/A
- KROS 0.47
- Revenue
- GROY $12,376,000.00
- KROS $232,844,000.00
- Revenue This Year
- GROY $82.74
- KROS $5,998.31
- Revenue Next Year
- GROY $51.73
- KROS N/A
- P/E Ratio
- GROY N/A
- KROS $33.74
- Revenue Growth
- GROY 90.37
- KROS 85820.30
- 52 Week Low
- GROY $1.16
- KROS $9.12
- 52 Week High
- GROY $4.04
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- GROY 58.55
- KROS 57.13
- Support Level
- GROY $3.55
- KROS $15.34
- Resistance Level
- GROY $3.87
- KROS $15.85
- Average True Range (ATR)
- GROY 0.20
- KROS 0.45
- MACD
- GROY -0.03
- KROS -0.02
- Stochastic Oscillator
- GROY 50.00
- KROS 57.08
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.